Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.33 -7.5%	$12.36	$8.04 ▼ $25.88	$361.52M	2.3	424,430 shs	1.20 million shs
FULC Fulcrum Therapeutics	$7.10 -3.8%	$6.02	$2.32 ▼ $10.13	$383.25M	2.41	918,717 shs	1.21 million shs
OLMA Olema Pharmaceuticals	$4.62 +1.3%	$4.69	$2.86 ▼ $16.62	$316.11M	1.99	824,299 shs	3.46 million shs
TELO Telomir Pharmaceuticals	$1.53 -10.0%	$2.21	$1.52 ▼ $8.40	$45.54M	-0.38	167,725 shs	2.25 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+8.46%	+4.71%	+15.11%	-45.55%
FULC Fulcrum Therapeutics	0.00%	+1.57%	+0.42%	+135.88%	+15.07%
OLMA Olema Pharmaceuticals	0.00%	+11.86%	-12.83%	+12.41%	-58.23%
TELO Telomir Pharmaceuticals	0.00%	-13.07%	-27.14%	-61.27%	-59.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	3.4677 of 5 stars	4.6	2.0	2.2	2.5	0.6
FULC Fulcrum Therapeutics	0.3358 of 5 stars	1.3	0.0	2.0	2.5	0.0
OLMA Olema Pharmaceuticals	2.6104 of 5 stars	3.5	1.0	3.3	2.5	0.6
TELO Telomir Pharmaceuticals	2.9908 of 5 stars	3.8	2.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	301.35% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-11.47% Downside
OLMA Olema Pharmaceuticals	3.00	Buy	$24.50	430.30% Upside
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	880.39% Upside

Current Analyst Ratings Breakdown

Latest TELO, ARCT, OLMA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/14/2025	OLMA Olema Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
5/14/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $22.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
4/28/2025	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.37	N/A	N/A	$8.90 per share	1.50
FULC Fulcrum Therapeutics	$80M	4.79	N/A	N/A	$4.51 per share	1.57
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$7.14 per share	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$2.01	N/A	N/A	N/A	N/A	-42.31%	-38.32%	8/5/2025 (Estimated)
TELO Telomir Pharmaceuticals	-$16.53M	-$0.42	N/A	N/A	N/A	N/A	-2,009.40%	-1,009.72%	8/12/2025 (Estimated)

Latest TELO, ARCT, OLMA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OLMA Olema Pharmaceuticals	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/12/2025	Q1 2025	TELO Telomir Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
FULC Fulcrum Therapeutics	N/A	28.71	28.71
OLMA Olema Pharmaceuticals	N/A	15.22	15.22
TELO Telomir Pharmaceuticals	N/A	0.75	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
FULC Fulcrum Therapeutics	89.83%
OLMA Olema Pharmaceuticals	91.78%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
FULC Fulcrum Therapeutics	7.00%
OLMA Olema Pharmaceuticals	16.36%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
OLMA Olema Pharmaceuticals	70	68.42 million	57.23 million	Optionable
TELO Telomir Pharmaceuticals	1	29.76 million	N/A	N/A

TELO, ARCT, OLMA, and FULC Headlines

Recent News About These Companies

Telomir Pharmaceuticals Reports Positive Preclinical Data

June 18, 2025 | tipranks.com

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

June 18, 2025 | accessnewswire.comA

Telomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s disease

June 14, 2025 | pharmabiz.comP

TELO Rises on Promising Telomir-1 Preclinical Results

June 13, 2025 | insidermonkey.com

TELO Rises on Promising Telomir-1 Preclinical Results

June 13, 2025 | msn.com

TELO Continues Trend of Significant Trial Announcements

June 11, 2025 | msn.com

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

June 11, 2025 | accessnewswire.comA

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated ...

June 7, 2025 | usatoday.com

TELO Data Indicates Aging Reversal Potential

June 6, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

June 5, 2025 | accessnewswire.comA

Telomir announces positive preclinical data for its novel oral AMD therapeutic

June 3, 2025 | ophthalmologytimes.comO

Telomir Pharmaceuticals Joins BIO Convention for Partnerships

June 2, 2025 | tipranks.com

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

June 2, 2025 | accessnewswire.comA

Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA ...

May 29, 2025 | finanznachrichten.de

TELO Produces Results with Exciting AMD Implications

May 29, 2025 | msn.com

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

May 29, 2025 | accessnewswire.comA

Telomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual Separation

May 21, 2025 | marketwatch.com

Telomir Pharmaceuticals Appoints New Chief Financial Officer

May 21, 2025 | tipranks.com

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

May 21, 2025 | accessnewswire.comA

Telomir Pharmaceuticals

May 19, 2025 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, ARCT, OLMA, and FULC Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.33 -1.08 (-7.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.98 +0.65 (+4.84%)

As of 06/27/2025 05:05 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Fulcrum Therapeutics NASDAQ:FULC

$7.10 -0.28 (-3.79%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.10 +0.01 (+0.07%)

As of 06/27/2025 04:34 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Olema Pharmaceuticals NASDAQ:OLMA

$4.62 +0.06 (+1.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.58 -0.04 (-0.95%)

As of 06/27/2025 07:05 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Telomir Pharmaceuticals NASDAQ:TELO

$1.53 -0.17 (-10.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.03 (+2.29%)

As of 06/27/2025 07:57 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time